Garduño-Orbe Brenda, Palma-Ramírez Paola Selene, López-Ortiz Eduardo, García-Morales Gabriela, Sánchez-Rebolledo Juan Manuel, Emigdio-Loeza Alexis, Gómez-García Anel, López-Ortiz Geovani
Unidad de Medicina Familiar Número 26, Instituto Mexicano del Seguro Social, Acapulco 39700, Guerrero, Mexico.
Unidad de Medicina Familiar No. 29 con UMAA, Instituto Mexicano del Seguro Social, Acapulco 39906, Guerrero, Mexico.
Infect Dis Rep. 2025 Jun 27;17(4):74. doi: 10.3390/idr17040074.
: Although COVID-19 vaccination has been effective in reducing severe illness and mortality, its differential clinical behavior in vaccinated and unvaccinated individuals during the early stages of the pandemic-especially in settings with partial coverage and real-world conditions-remains insufficiently characterized. : To assess differences in clinical presentation, comorbidity prevalence, hospitalization, and mortality between vaccinated and unvaccinated patients diagnosed with SARS-CoV-2 during the early phase of the pandemic. : An analytical cross-sectional study was conducted using 4625 electronic medical records of patients diagnosed with COVID-19 in Guerrero, Mexico, between 1 January and 31 December 2021. Variables included vaccination status, age, sex, comorbidities, symptom severity, clinical outcomes, and mortality. Statistical analyses involved chi-square tests, logistic regression for hospitalization probability, and Cox proportional hazards models for mortality risk. : Of the patients analyzed, 31.45% had received at least one vaccine dose. Fever, headache, cough, and anosmia were more frequent among vaccinated individuals ( < 0.001). Prostration and chest pain were strongly associated with hospitalization in both groups. In unvaccinated patients, smoking (OR = 4.75), obesity (OR = 3.85), and hypertension (OR = 2.94) increased hospitalization risk. Among vaccinated patients, diabetes mellitus (OR = 3.62) and hypertension (OR = 2.88) were key predictors. Vaccination was significantly associated with lower odds of hospitalization (OR = 0.38; 95% CI: 0.26-0.55) and reduced mortality risk (HR = 0.24; 95% CI: 0.08-0.71). : Vaccination status was a significant protective factor for both hospitalization and mortality; however, clinical symptoms and comorbidity-related risks varied, highlighting the need for individualized patient management strategies.
虽然新冠病毒疫苗接种在降低重症和死亡率方面已见成效,但其在疫情早期接种和未接种人群中的临床差异表现——尤其是在部分接种覆盖和现实条件下——仍未得到充分描述。 为评估在疫情早期被诊断为感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的接种和未接种患者之间的临床表现、合并症患病率、住院率和死亡率差异。 采用分析性横断面研究,使用了2021年1月1日至12月31日期间墨西哥格雷罗州4625例被诊断为新冠病毒病(COVID-19)患者的电子病历。变量包括疫苗接种状况、年龄、性别、合并症、症状严重程度、临床结局和死亡率。统计分析包括卡方检验、住院概率的逻辑回归以及死亡风险的Cox比例风险模型。 在分析的患者中,31.45%至少接种过一剂疫苗。接种者中发热、头痛、咳嗽和嗅觉丧失更为常见(<0.001)。两组中乏力和胸痛与住院密切相关。在未接种患者中,吸烟(比值比[OR]=4.75)、肥胖(OR=3.85)和高血压(OR=2.94)增加住院风险。在接种患者中,糖尿病(OR=3.62)和高血压(OR=2.88)是关键预测因素。接种疫苗与较低的住院几率(OR=0.38;95%置信区间[CI]:0.26 - 0.55)和降低的死亡风险(风险比[HR]=0.24;95%CI:0.08 - 0.71)显著相关。 疫苗接种状况是住院和死亡的重要保护因素;然而,临床症状和合并症相关风险存在差异,凸显了个性化患者管理策略的必要性。
Cochrane Database Syst Rev. 2022-5-20
BMC Pregnancy Childbirth. 2022-2-28
Cochrane Database Syst Rev. 2022-11-17
Cochrane Database Syst Rev. 2023-1-9
Cochrane Database Syst Rev. 2022-9-20
Trans R Soc Trop Med Hyg. 2025-1-3
Lancet Reg Health Am. 2023-10-31
Lancet Respir Med. 2023-5